The ACCORD Study Group. NEJM 2010; Epub March 14

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Trial profile Fox K et al. Lancet 2008;372:

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Clinical Outcomes with Newer Antihyperglycemic Agents

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Journal Club 埼玉医科大学総合医療センター内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田昌文 Matsuda, Masafumi.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

The SPRINT Research Group

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Copyright © 2009 American Medical Association. All rights reserved.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

LEADER trial: Primary Outcome

Fig. 1. Mean plasma lipid and lipoprotein levels as a function of the common genetic variants in LCAT, g.-293G>A, S208T, and L369L in the CCHS and S208T.

Copyright © 2009 American Medical Association. All rights reserved.

AIM HIGH Niacin plus Statin to prevent vascular events

First time a CETP inhibitor shows reduction of serious CV events

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

TNT Study: Baseline Characteristics of the Patients

Fellström BC, et al. N Engl J Med 2009;360:1455-7

II. assessment of dyslipidemias

Coronary artery bypass grafting in diabetics: A growing health care cost crisis Sajjad Raza, MD, Joseph F. Sabik, MD, Ponnuthurai Ainkaran, MS, Eugene.

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Plus–minus values are means ±SE

Daan Kromhout, et al. NEJM epub August 29, 2010

Cumulative incidences of events, according to glucose-control strategy

Characteristics of the Patients at Baseline*

Baseline Characteristics According to Sex

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Baseline Characteristics of the Subjects*

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Baseline Characteristics of the Patients – Part I

The ACCORD Study Group. NEJM 2010; Epub March 14

Characteristics of included studies

Baseline Characteristics of the Patients - Part I

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

International Journal of Cardiology

Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients Peter P. Toth, MD, PhD, Sephy Philip,

Presentation transcript:

The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Characteristics of the Patients* - Part I The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Characteristics of the Patients* - Part II The ACCORD Study Group. NEJM 2010; Epub March 14

Lipid Values The ACCORD Study Group. NEJM 2010; Epub March 14 Shown are mean plasma levels of total cholesterol (Panel A), low-density lipoprotein (LDL) cholesterol (Panel B), and high-density lipoprotein (HDL) cholesterol (Panel C) and median levels of triglycerides (Panel D) at baseline, 4 months, 8 months, 1 year, and annually thereafter. Nominal P values for differences between the study groups at 4 months and at the end of the study were, respectively: total cholesterol, P<0.001 and P = 0.02; LDL cholesterol, P = 0.11 and P = 0.16; HDL cholesterol, P<0.001 and P=0.01; and triglycerides, P<0.001 for both comparisons with the use of nonparametric tests. End-of-study visits were those that occurred in early 2009 and included follow- up at years 4, 5, 6, and 7. The I bars represent 95% confidence intervals. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. The ACCORD Study Group. NEJM 2010; Epub March 14

Prespecified Primary and Secondary Outcomes The ACCORD Study Group. NEJM 2010; Epub March 14

Kaplan–Meier Analyses of the Primary Outcome, Expanded Macrovascular Outcome, and Death Shown are the cumulative incidence of the primary outcome (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (Panel A), the expanded macrovascular outcome (a combination of the primary outcome plus revascularization or hospitalization for congestive heart failure) (Panel B), and death from any cause (Panel C) or from cardiovascular causes (Panel D) during follow- up. The insets show close-up versions of the graphs in each panel. The ACCORD Study Group. NEJM 2010; Epub March 14

Hazard Ratios for the Primary Outcome in Prespecified Subgroups The horizontal bars represent 95% confidence intervals, and the vertical dashed line indicates the overall hazard ratio. The size of each square is proportional to the number of patients. P values are for tests for interaction. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. The ACCORD Study Group. NEJM 2010; Epub March 14

Comparison of the ACCORD Lipid Trial to Earlier Fibrate Trials The ACCORD Study Group. NEJM 2010; Epub March 14